GlassScriptPhysician profile
Yasmin Masood
NPI 1821122722
$1,584.47
in general payments reported to CMS, 2019-2025
23 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $296 · 2021: $743 · 2022: $187 · 2023: $57.43 · 2024: $115 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $281.31 | 2021-2022 | |
| Amarin Pharma, INC. | $154.70 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $138.97 | 2020-2021 | |
| Medtronic Vascular, INC. | $130.21 | 2020 | |
| Boston Scientific Corporation | $124.99 | 2021 | |
| Merck Sharp & Dohme LLC | $119.49 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $112.36 | 2021-2025 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $82.31 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $80.99 | 2020-2025 | |
| Amgen INC. | $55.24 | 2020-2021 | |
| Novo Nordisk INC | $46.50 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.51 | 2025 | Jardiance |
| Pfizer INC. | $34.83 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.16 | 2022 | |
| Bardy Diagnostics, INC. | $30.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $18.72 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $18.50 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.25 | 2025 | Lifevest |
| Insightec,INC | $15.50 | 2025 | Exablate |
| Horizon Therapeutics Plc | $14.93 | 2020 | |
| Lilly USA, LLC | $13.84 | 2021 | |
| Scpharmaceuticals INC. | $13.35 | 2024 | |
| Akcea Therapeutics, INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.